Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma

Sponsor
Children's Cancer and Leukaemia Group
Study ID
NCT00287976
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 20 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating young patients with refractory or recurrent hepatoblastoma.

Key Dates

Start date
Apr 30, 2003
Status verified
Jun 2009
Primary completion
Dec 31, 2008

Study Design

Enrollment
30 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Best overall response (complete response and partial response)

Related Studies